MARKET

RGLS

RGLS

Regulus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.270
-0.070
-5.22%
After Hours: 1.240 -0.03 -2.36% 18:10 03/03 EST
OPEN
1.320
PREV CLOSE
1.340
HIGH
1.340
LOW
1.145
VOLUME
2.15M
TURNOVER
--
52 WEEK HIGH
1.970
52 WEEK LOW
0.4222
MARKET CAP
49.74M
P/E (TTM)
-1.6868
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO
CNW Group · 1d ago
MicroRNA Market Worth USD 613.2 Million at 13.4% CAGR by 2027 Backed by Increasing Number of Clinical Trials in North America
Feb 25, 2021 (The Expresswire) -- The global microRNA market size is expected to showcase exponential growth by reaching USD 613.2 million by 2027 while...
The Express Wire · 6d ago
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)
Benzinga · 02/18 13:14
8-K: Regulus Therapeutics Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/17 22:59
--Analyst Actions: Wedbush Adjusts Price Target on Regulus Therapeutics to $2 From $1, Maintains Neutral Rating
MT Newswires · 02/17 10:09
Regulus Therapeutics gains on completion of enrollment in study of RGLS4326 for kidney disease
Regulus Therapeutics (RGLS) soars 18% after completing enrollment of the first cohort of patients into its Phase 1b clinical study of RGLS4326.The study is designed to evaluate the safety, pharmacokinetics, and changes
Seekingalpha · 02/10 13:37
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of the first cohort of patients i...
PR Newswire - PRF · 02/10 13:07
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10)
Benzinga · 02/10 12:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGLS. Analyze the recent business situations of Regulus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGLS stock price target is 1.333 with a high estimate of 2.000 and a low estimate of 0.5000.
EPS
Institutional Holdings
Institutions: 58
Institutional Holdings: 19.48M
% Owned: 49.74%
Shares Outstanding: 39.16M
TypeInstitutionsShares
Increased
8
4.98M
New
17
5.65M
Decreased
3
27.77K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Stelios Papadopoulos
President/Chief Executive Officer/Director
Joseph Hagan
Chief Financial Officer
Crispina Calsada
Senior Vice President/General Counsel
Christopher Aker
Chief Scientific Officer
Denis Drygin
Director
Alice Huang
Independent Director
David Baltimore
Independent Director
Kathryn Collier
Independent Director
Jake Nunn
Independent Director
William Rastetter
Independent Director
Hugh Rosen
Independent Director
Simos Simeonidis
Independent Director
Pascale Witz
  • Dividends
  • Splits
  • Insider Activity
No Data
About RGLS
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Webull offers kinds of Regulus Therapeutics Inc stock information, including NASDAQ:RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.